Everyone Wins in This Big Pharma Buyout

Shares of Mallinckrodt (NYSE: MNK  ) were up 10% after the company announced that it's buying Cadence (NASDAQ: CADX  ) for $1.3 billion. Shares of Cadence performed even better, up about 25% on the buyout news.

The catalyst for the acquisition is painkiller Ofirmev, which was approved in 2010, but with roughly $100 million in trailing-12-month sales, it hasn't been a huge seller. Mallinckrodt believes it can double those sales, and in this video from Tuesday's Market Checkup, Motley Fool health-care analyst David Williamson says he thinks the company will need to reach that goal to fully justify this purchase.

If everything goes well, this purchase should be accretive this year, which is what had the market showing love to both of these companies on the news. Mallinckrodt is focused on growing its specialty pharma side, and already specializes in abuse-resistant painkillers. In the video, David gives investors the story on Mallinckrodt, and discusses why he now sees this spec pharma company as a possible acquisition target itself.

What's the best way for investors to play the volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 13, 2014, at 11:16 AM, builder973 wrote:

    David,

    FYI you comments about this deal show you haven't a clue about the sales of Cadence or the economics of the deal for Mailnkrodt. Perhaps you should research the facts before you comment in a manner that shows you have no clue about the deal.

Add your comment.

DocumentId: 2837353, ~/Articles/ArticleHandler.aspx, 4/24/2014 11:20:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement